このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC (PSMA-DaroRT)

2026年9月6日 更新者:Hao Zeng、West China Hospital

A Multicenter, Prospective, Randomized Controlled Phase II Trial of PSMA PET/CT-Guided Stereotactic Body Radiotherapy Combined With Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy. Participants whose cancer has not progressed and who still have active tumor lesions on prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) will then be randomly assigned to one of two groups. One group will continue darolutamide plus androgen deprivation therapy. The other group will receive stereotactic body radiotherapy (SBRT) to all active tumor lesions identified by PSMA PET/CT, while continuing darolutamide plus androgen deprivation therapy. The main purpose of this study is to find out whether adding PSMA PET/CT-guided SBRT can help participants live longer without tumor growth seen on scans or death. The study will also evaluate prostate-specific antigen (PSA) changes, time to castration-resistant prostate cancer, overall survival, side effects, and quality of life.

調査の概要

詳細な説明

Metastatic hormone-sensitive prostate cancer is usually treated with systemic therapy, including androgen deprivation therapy and androgen receptor pathway inhibitors such as darolutamide. However, some patients still have active tumor lesions after initial systemic treatment, and these residual lesions may contribute to later disease progression.

This study is designed to test whether adding targeted radiotherapy to residual active tumor lesions can improve disease control. All enrolled participants will first receive 6 months of darolutamide plus androgen deprivation therapy. After this initial treatment period, participants will undergo clinical and imaging assessment, including prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), to evaluate whether active tumor lesions remain.

Participants who have no disease progression and still have PSMA PET/CT-positive active tumor lesions will be randomly assigned in a 1:1 ratio to one of two groups. Participants in the control group will continue darolutamide plus androgen deprivation therapy. Participants in the experimental group will continue darolutamide plus androgen deprivation therapy and will also receive stereotactic body radiotherapy (SBRT) to all active tumor lesions identified by PSMA PET/CT, including active lesions in the prostate or prostate bed and metastatic sites when appropriate.

This is a multicenter, prospective, randomized, open-label phase 2 study. The study plans to enroll about 254 men with metastatic hormone-sensitive prostate cancer. The main question is whether PSMA PET/CT-guided SBRT, when added to darolutamide and androgen deprivation therapy after 6 months of initial systemic treatment, can increase the proportion of participants who are alive without radiographic disease progression at 3 years after randomization.

Participants will be followed regularly with physical examinations, blood tests including prostate-specific antigen (PSA), testosterone monitoring when required, imaging examinations, assessment of adverse events, and quality-of-life questionnaires. Imaging-based disease progression will be assessed using standard criteria for soft tissue and bone lesions. Safety will be monitored throughout the study, including side effects related to darolutamide, androgen deprivation therapy, and radiotherapy.

The study will also explore whether PSMA PET/CT imaging features, PSA changes, circulating tumor DNA, and molecular features of tumor or blood samples are associated with treatment response, disease progression, or survival outcomes. These exploratory analyses may help identify future biomarkers for selecting patients who are more likely to benefit from combined systemic therapy and PSMA PET/CT-guided radiotherapy.

研究の種類

介入

入学 (推定)

254

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Hao Zeng, MD, PhD
  • 電話番号:86 28 85422026
  • メール:kucaizeng@163.com

研究場所

    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • West China Hospital, Sichuan University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Male participants aged ≥18 years and <85 years.
  • Histologically confirmed prostate adenocarcinoma.
  • No neuroendocrine carcinoma, ductal adenocarcinoma, small-cell carcinoma, signet-ring cell carcinoma, or sarcomatoid carcinoma component.
  • Metastatic prostate cancer confirmed by imaging and/or pathological evidence.
  • Baseline PSMA PET/CT assessment demonstrates a total of ≤20 metastatic lesions.
  • No prior radical prostatectomy or radiotherapy for prostate cancer.
  • No prior systemic anti-tumor therapy that may affect the efficacy assessment of this study, including androgen receptor signaling inhibitors (ARSIs; e.g., abiraterone, enzalutamide, apalutamide, rezvilutamide, or darolutamide), chemotherapy, PARP inhibitors, radionuclide therapy, or other such treatments.
  • Short-term androgen deprivation therapy (ADT) and/or first-generation antiandrogen therapy prior to enrollment is permitted, provided that the interval from the first initiation of any such treatment to the date of enrollment does not exceed 3 months (≤12 weeks).
  • Expected survival >12 months.
  • Able to understand the study and voluntarily sign written informed consent.
  • Able and willing to comply with study visits and protocol procedures.
  • Willing to provide tumor tissue, blood, and other biological samples as required by the study protocol.
  • Absolute neutrophil count ≥1.5 × 10^9/L.
  • Platelet count ≥100 × 10^9/L.
  • Hemoglobin ≥90 g/L.
  • Total bilirubin ≤1.5 × upper limit of normal.
  • Alanine aminotransferase and aspartate aminotransferase ≤2.5 × upper limit of normal.
  • Serum albumin ≥20 g/L.
  • Serum creatinine ≤1.5 × upper limit of normal or creatinine clearance ≥50 mL/min.
  • Eastern Cooperative Oncology Group performance status ≤2.

Exclusion Criteria:

  • Current or prior history of another primary malignancy.
  • History of another malignancy within 3 years that differs from the study cancer in primary site or histology.
  • History of papillary thyroid carcinoma is allowed if it is well controlled.
  • History of basal cell carcinoma of the skin is allowed if it is well controlled.
  • History of squamous cell carcinoma of the skin is allowed if it is well controlled.
  • History of cervical carcinoma in situ is allowed if it is well controlled.
  • Prior radical prostatectomy.
  • Prior external beam radiotherapy.
  • Prior radical or ablative local therapy for prostate cancer.
  • Prior treatment with an androgen receptor signaling inhibitor, including abiraterone, enzalutamide, apalutamide, rezvilutamide, or darolutamide.
  • Prior chemotherapy for prostate cancer.
  • Major surgery within 4 weeks before enrollment.
  • Serious trauma within 4 weeks before enrollment.
  • Contraindication to radiotherapy.
  • Spinal cord compression.
  • Active enteritis.
  • Severe pelvic infection.
  • Inability to maintain the required body position for radiotherapy.
  • History of allergy to PET/CT tracer.
  • Nuclear medicine assessment showing super bone imaging.
  • Marked discordance between PSMA PET/CT and FDG PET/CT findings.
  • Disease progression during the 6-month run-in period of androgen deprivation therapy plus darolutamide before randomization.
  • Unacceptable toxicity during the 6-month run-in period of androgen deprivation therapy plus darolutamide before randomization.
  • No active tumor lesion on PSMA PET/CT after the 6-month run-in period.
  • Allergy to any component of the study treatment.
  • Active or poorly controlled serious infection.
  • Human immunodeficiency virus infection.
  • Acute or chronic active hepatitis B infection, defined as positive hepatitis B surface antigen with hepatitis B virus DNA >1 × 10^3/mL.
  • Acute or chronic active hepatitis C infection, defined as positive hepatitis C virus antibody with hepatitis C virus RNA >15 IU/mL.
  • Active pulmonary tuberculosis.
  • Other serious infectious disease.
  • New York Heart Association class III or IV congestive heart failure.
  • Persistent symptomatic arrhythmia.
  • Uncontrolled atrial fibrillation.
  • Left ventricular ejection fraction below the lower limit of normal on repeated echocardiographic assessments.
  • Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg.
  • Arterial thrombotic, embolic, or ischemic event within 6 months before enrollment.
  • Myocardial infarction within 6 months before enrollment.
  • Unstable angina within 6 months before enrollment.
  • Cerebrovascular accident within 6 months before enrollment.
  • Transient ischemic attack within 6 months before enrollment.
  • Medical condition requiring warfarin or coumarin anticoagulation therapy.
  • Uncontrolled hypercalcemia, defined as ionized calcium >1.5 mmol/L, total calcium >12 mg/dL, or corrected serum calcium above the upper limit of normal.
  • Symptomatic hypercalcemia requiring continuous bisphosphonate therapy.
  • Uncontrolled adrenal insufficiency.
  • History of abdominal fistula within 6 months before enrollment.
  • History of gastrointestinal perforation within 6 months before enrollment.
  • History of intra-abdominal abscess within 6 months before enrollment.
  • Severe non-healing wound.
  • Severe non-healing ulcer.
  • Gastrointestinal disease that may impair absorption.
  • Active peptic ulcer disease.
  • Uncontrolled nausea.
  • Uncontrolled vomiting.
  • Uncontrolled diarrhea.
  • History of small bowel resection that may impair drug absorption.
  • Other acute or chronic disease, psychiatric disorder, or laboratory abnormality that may increase the risk associated with study participation or study treatment.
  • Other acute or chronic disease, psychiatric disorder, or laboratory abnormality that may interfere with interpretation of study results.
  • Any other medical or psychological condition that, in the investigator's judgment, may affect participant safety, compliance, or study integrity.
  • Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:PSMA PET/CT-Guided SBRT + Darolutamide + ADT
After a 6-month run-in period of darolutamide plus androgen deprivation therapy, eligible participants without disease progression and with residual PSMA PET/CT-positive active tumor lesions will receive PSMA PET/CT-guided stereotactic body radiotherapy to all active tumor lesions while continuing darolutamide plus androgen deprivation therapy.
Stereotactic body radiotherapy will be delivered in the experimental arm after the 6-month run-in period of darolutamide plus androgen deprivation therapy. Radiotherapy will target all residual PSMA PET/CT-positive active tumor lesions, while participants continue darolutamide plus androgen deprivation therapy. Target lesions may include active lesions in the prostate or prostate bed and metastatic sites. Dose and fractionation will be selected according to lesion location, lesion size, and organ-at-risk constraints as specified in the study protocol.
Darolutamide will be administered orally at 600 mg twice daily with food during the 6-month run-in period in combination with androgen deprivation therapy. After randomization, darolutamide will be continued in both treatment groups according to the assigned treatment strategy. Treatment may be interrupted or dose-reduced according to protocol-defined toxicity management rules.
Androgen deprivation therapy will be maintained throughout study treatment in both groups. The method of androgen deprivation therapy will be selected by the investigator according to the participant's clinical condition and may include surgical castration or medical castration with a luteinizing hormone-releasing hormone agonist or antagonist. Treatment will aim to maintain castrate testosterone levels according to the study protocol.
アクティブコンパレータ:Darolutamide + ADT
After a 6-month run-in period of darolutamide plus androgen deprivation therapy, eligible participants without disease progression and with residual PSMA PET/CT-positive active tumor lesions will continue darolutamide plus androgen deprivation therapy without local radiotherapy.
Darolutamide will be administered orally at 600 mg twice daily with food during the 6-month run-in period in combination with androgen deprivation therapy. After randomization, darolutamide will be continued in both treatment groups according to the assigned treatment strategy. Treatment may be interrupted or dose-reduced according to protocol-defined toxicity management rules.
Androgen deprivation therapy will be maintained throughout study treatment in both groups. The method of androgen deprivation therapy will be selected by the investigator according to the participant's clinical condition and may include surgical castration or medical castration with a luteinizing hormone-releasing hormone agonist or antagonist. Treatment will aim to maintain castrate testosterone levels according to the study protocol.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
3-Year Radiographic Progression-Free Survival (rPFS)
時間枠:From randomization to 3 years after randomization
Radiographic progression-free survival (rPFS) is defined as the time from randomization to radiographic disease progression or death from any cause, whichever occurs first. Progression is assessed using RECIST 1.1 for soft tissue and PCWG3 criteria for bone lesions. The 3-year rPFS rate will be estimated using the Kaplan-Meier method.
From randomization to 3 years after randomization

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Radiographic Progression-Free Survival (o-rPFS)
時間枠:From first dose of induction therapy to radiographic progression or death, assessed up to 60 months
Overall radiographic progression-free survival is defined as the time from the first dose of induction therapy with darolutamide plus androgen deprivation therapy to the first occurrence of radiographic disease progression or death from any cause, whichever occurs first. Radiographic progression will be assessed according to RECIST 1.1 for soft-tissue lesions and PCWG3 criteria for bone lesions.
From first dose of induction therapy to radiographic progression or death, assessed up to 60 months
PSA Progression-Free Survival (PSA-PFS)
時間枠:From randomization to PSA progression or death, assessed up to 60 months
PSA progression-free survival is defined as the time from randomization to PSA progression per PCWG3 criteria or death from any cause, whichever occurs first. For participants with a PSA decline from baseline, PSA progression is defined as a ≥25% increase and an absolute increase of ≥2 ng/mL from the PSA nadir, confirmed by a second consecutive value obtained ≥3 weeks later. For participants without a PSA decline from baseline, PSA progression is defined as a ≥25% increase from baseline with an absolute increase of ≥2 ng/mL after 12 weeks of treatment.
From randomization to PSA progression or death, assessed up to 60 months
Time to Castration-Resistant Prostate Cancer (CRPC)
時間枠:From randomization to development of castration-resistant prostate cancer, assessed up to 60 months
Time to castration-resistant prostate cancer is defined as the time from randomization to the development of castration-resistant prostate cancer under castrate testosterone levels, defined as serum testosterone <50 ng/dL or <1.7 nmol/L. Castration-resistant prostate cancer is defined by biochemical progression, radiographic progression, or unequivocal clinical progression according to protocol-defined criteria.
From randomization to development of castration-resistant prostate cancer, assessed up to 60 months
Overall Survival (OS)
時間枠:From randomization to death from any cause, assessed up to 60 months
Overall survival is defined as the time from randomization to death from any cause.
From randomization to death from any cause, assessed up to 60 months
PSA Response Rate (≥50% Decline From Baseline)
時間枠:From randomization to PSA response, assessed up to 36 months
PSA response rate is defined as the proportion of participants who achieve a ≥50% decline in serum PSA from baseline (at randomization) at any time during treatment, confirmed by at least one repeat measurement approximately 4 weeks later.
From randomization to PSA response, assessed up to 36 months
Best Percent Change in PSA From Baseline
時間枠:From randomization up to 36 months
Best percent change in PSA from baseline is defined as the maximum percent decrease from baseline PSA at randomization to the lowest observed PSA value during follow-up.
From randomization up to 36 months
PSA Nadir
時間枠:From randomization up to 36 months
PSA nadir is defined as the lowest serum PSA value observed from randomization through the end of prespecified follow-up.
From randomization up to 36 months
Time to PSA Nadir
時間枠:From randomization up to 36 months
Time to PSA nadir is defined as the time from randomization to the date when the lowest serum PSA value is first observed.
From randomization up to 36 months
Incidence and Severity of Adverse Events
時間枠:From first study treatment to 30 days after the last study treatment or radiotherapy, whichever occurs later
Safety will be assessed by the incidence and severity of treatment-emergent adverse events, treatment-emergent serious adverse events, adverse events of special interest, darolutamide-related adverse events, adverse events leading to treatment discontinuation, and adverse events with fatal outcome. Adverse events will be graded according to CTCAE v6.0.
From first study treatment to 30 days after the last study treatment or radiotherapy, whichever occurs later
Quality of Life (EORTC QLQ-C30)
時間枠:Baseline at randomization and prespecified follow-up visits up to 36 months
Quality of life will be assessed using EORTC QLQ-C30 questionnaires. Scores and changes from baseline over time will be summarized and compared between treatment groups.
Baseline at randomization and prespecified follow-up visits up to 36 months
Quality of Life (QLQ-PR25)
時間枠:Baseline at randomization and prespecified follow-up visits up to 36 months
Quality of life will be assessed using EORTC QLQ-PR25 questionnaires. Scores and changes from baseline over time will be summarized and compared between treatment groups.
Baseline at randomization and prespecified follow-up visits up to 36 months
Quality of Life (EQ-5D)
時間枠:Baseline at randomization and prespecified follow-up visits up to 36 months
Quality of life will be assessed using EQ-5D questionnaires. Scores and changes from baseline over time will be summarized and compared between treatment groups.
Baseline at randomization and prespecified follow-up visits up to 36 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Hao Zeng, MD, PhD、West China Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月15日

一次修了 (推定)

2031年8月1日

研究の完了 (推定)

2031年10月1日

試験登録日

最初に提出

2026年6月7日

QC基準を満たした最初の提出物

2026年6月14日

最初の投稿 (実際)

2026年6月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月10日

QC基準を満たした最後の更新が送信されました

2026年9月6日

最終確認日

2026年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

Individual participant data (IPD) sharing has not been decided at this time. Any future sharing will be considered after study completion and publication, subject to IRB/ethics approval, applicable regulations, participant privacy protections, and data use agreements. Requests, if allowed, would require submission of a research proposal and will be evaluated by the study team.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する